#American Society of Clinical Oncology (ASCO)

ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer

Innovent Biologics Announcement at ASCO Innovent Biologics , Inc. ( HKEX: 01801 )(OTC: IVBXF ) announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310 (anti-CTLA-...

P

Prohost Biotech

Jun 13, 2024

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Moderna to Host Investor Event Via Webcast Moderna, Inc. ( MRNA ) announced that three abstracts on mRNA-4157 ( V940 ), an investigational mRNA individualized neoantigen therapy, have been accepted fo...

P

Prohost Biotech

May 23, 2024

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Compugen Updated Trial Data Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology ( ASCO ) 2021 Annual Meeting Milestone ri...

P

Prohost Biotech

May 13, 2021

Gilead Sciences Conference Call Information. See Also: Compugen Announcements

Gilead Sciences First-Quarter 2021 Financial Results Conference Call Info Gilead Sciences ( GILD ) management will host a conference call to discuss the company’s first-quarter 2021 financial results...

P

Prohost Biotech

Apr 29, 2021

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX ( CTMX ) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® techno...

P

Prohost Biotech

Apr 30, 2020

Amgen's Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

Amgen's Outperforming After being boxed in, for the past couple of weeks, Amgen’s ( AMGN ) stock finally outperformed. The firm was outperforming silently with regard to its financial results, science...

P

Prohost Biotech

Sep 9, 2019

The Nektar Good News Cannot be Hidden Any Longer

Nektar Therapeutics We believe that Nektar Therapeutics ( NKTR ) is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we...

P

Prohost Biotech

Aug 1, 2019

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observ...

P

Prohost Biotech

Jun 4, 2019

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

Amgen, the Biotech King A mgen ( AMGN ) , the biotech king, wanted to buy all of the Denmark biotech firm Nuevolution's drug discovery platform. This platform attracted Amgen in 2016 as well as many o...

P

Prohost Biotech

May 24, 2019

Why Portola couldn’t flex its muscles or use them yet

All the buying and selling of Portola (PTLA) will not make any sense to us until the firm fulfills its obligations towards what is required by the authorities, by health care and by private third-par...

P

Prohost Biotech

Aug 9, 2018

Good News, Bad News & Comebacks. See Also: ASCO Results

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech firms, and giant biopharmaceutical firms, in addition to some private biot...

P

Prohost Biotech

Jun 19, 2018

More promising news for Array from its melanoma combination clinical trial

Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF -mutant advanced melanoma. The results showed that the median overall survival (mOS ) was 33.6 months for pa...

P

Prohost Biotech

Jun 5, 2018

About Nektar’s product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was viewed as positive by many analysts and investor un...

P

Prohost Biotech

Jun 4, 2018

Prohost Letter #410

Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of drugs belonging to companies that Prohost has picked for investment. Usually, granting approvals rallies the sto...

P

Prohost Biotech

Jun 13, 2017

1m

9

News & Comments

Juno Also has Great News from Its CAR-T Cell Approach

Juno’s (JUNO) JCAR017 and JCAR014 are chimeric antigen receptor T cell (CAR-T) product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies. These malignan...

P

Prohost Biotech

Jun 8, 2017

4m

2

News & Comments

Bluebird Flies Sky-High with Its CAR-T Wings

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was well received at ASCO after the firm stated results demonstrating that all the 15 evaluable patients i...

P

Prohost Biotech

Jun 7, 2017

Data From ASCO and Data from the Internet

As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology meeting (ASCO) is further elaborating on Checkpoint inhibition and chimeric antigen receptor T...

P

Prohost Biotech

Jun 6, 2017

Prohost Letter #409

Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. The Meeting, which will begin on Friday June 2, 2017 and will end on Monday 5, 2017 will be diff...

P

Prohost Biotech

May 25, 2017

Le CompaGnon Part 2

Le Compa G non Part 2 Wednesday June 22, 2016 From the American Society of Clinical Oncology (ASCO) Checkpoint inhibitors the CAR T Approach Adoptive cell therapy Oncolytic virus ther...

P

Prohost Biotech

Jun 23, 2016

Le CompaGnon Part 1

Le Compa G non Part 1 TUESDAY June 14, 2016 The Eternal Market Games Unfortunately, the fabrication and misrepresentation of reality in media articles about member firms of the biotech sector succeede...

P

Prohost Biotech

Jun 14, 2016

1m

1